organization · Reporting owner
Cambridge Innovation Capital (Jersey) Ltd
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BICYCLE THERAPEUTICS PLCBCYC · Entity 5993 | 10% owner | May 28, 2019 | May 31, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BICYCLE THERAPEUTICS PLC
Report date May 28, 2019 · Filed May 31, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 1,751,437 |
Ending reported balance
After 2019-05-29 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2019-05-28 · Conversion · Acquired 1,081,823 · Balance 1,081,823 F1: Each Series B1 and B2 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date. Row 2 · 2019-05-28 · Other · Acquired 125,587 · Balance 1,207,410 F1: Each Series B1 and B2 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date. Row 3 · 2019-05-28 · Conversion · Acquired 229,741 · Balance 1,437,151 F1: Each Series B1 and B2 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date. Row 4 · 2019-05-29 · Purchase · Acquired 314,286 · Balance 1,751,437 |
| Series B1 Preferred SharesSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2019-05-28 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-05-28 · Conversion · Disposed 1,081,823 · Balance 0 F1: Each Series B1 and B2 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date. |
| Series B1 Preferred Shares WarrantsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2019-05-28 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-05-28 · Other · Disposed 125,587 · Balance 0 F2: Upon conversion of all of the Series B1 Preferred Shares into Ordinary Shares in connection with the Issuer's initial public offering, the Warrants became exercisable for Ordinary Shares. The Warrants had an exercise price of a nominal value per share and were exercised immediately prior to completion of the Issuer's initial public offering. F1: Each Series B1 and B2 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date. |
| Series B2 Preferred SharesSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2019-05-28 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-05-28 · Conversion · Disposed 229,741 · Balance 0 F1: Each Series B1 and B2 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Series B1 and B2 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date.
F2: Upon conversion of all of the Series B1 Preferred Shares into Ordinary Shares in connection with the Issuer's initial public offering, the Warrants became exercisable for Ordinary Shares. The Warrants had an exercise price of a nominal value per share and were exercised immediately prior to completion of the Issuer's initial public offering.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 29, 2019 Filed May 31, 2019 21:12 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | PurchaseOrdinary Shares | 314,286 | $14.00 | $4,400,004.00 |
DisclosureSEC source: 0001104659-19-033169 · a4.xml · nonDerivative · entry 4 Cambridge Innovation Capital (Jersey) Ltd · CIK 0001776911 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,751,437 Read SEC document |
| May 28, 2019 Filed May 31, 2019 21:12 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | ConversionSeries B2 Preferred Shares · Derivative | 229,741 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-033169 · a4.xml · derivative · entry 7 Cambridge Innovation Capital (Jersey) Ltd · CIK 0001776911 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 229,741 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Series B1 and B2 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date. F1 · price: Each Series B1 and B2 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.exercise_date: Each Series B1 and B2 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.expiration_date: Each Series B1 and B2 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date. Read SEC document |
| May 28, 2019 Filed May 31, 2019 21:12 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | OtherSeries B1 Preferred Shares Warrants · Derivative | 125,587 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-033169 · a4.xml · derivative · entry 6 Cambridge Innovation Capital (Jersey) Ltd · CIK 0001776911 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 125,587 shares Expires not disclosed F2 · security: Upon conversion of all of the Series B1 Preferred Shares into Ordinary Shares in connection with the Issuer's initial public offering, the Warrants became exercisable for Ordinary Shares. The Warrants had an exercise price of a nominal value per share and were exercised immediately prior to completion of the Issuer's initial public offering. F1 · derivative.exercise_price: Each Series B1 and B2 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date. F1 · price: Each Series B1 and B2 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.exercise_date: Each Series B1 and B2 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.expiration_date: Each Series B1 and B2 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.underlying: Each Series B1 and B2 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date. Read SEC document |
| May 28, 2019 Filed May 31, 2019 21:12 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | ConversionSeries B1 Preferred Shares · Derivative | 1,081,823 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-033169 · a4.xml · derivative · entry 5 Cambridge Innovation Capital (Jersey) Ltd · CIK 0001776911 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 1,081,823 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Series B1 and B2 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date. F1 · price: Each Series B1 and B2 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.exercise_date: Each Series B1 and B2 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.expiration_date: Each Series B1 and B2 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date. Read SEC document |
| May 28, 2019 Filed May 31, 2019 21:12 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | ConversionOrdinary Shares | 229,741 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-033169 · a4.xml · nonDerivative · entry 3 Cambridge Innovation Capital (Jersey) Ltd · CIK 0001776911 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,437,151 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Series B1 and B2 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date. Read SEC document |
| May 28, 2019 Filed May 31, 2019 21:12 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | OtherOrdinary Shares | 125,587 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-033169 · a4.xml · nonDerivative · entry 2 Cambridge Innovation Capital (Jersey) Ltd · CIK 0001776911 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,207,410 F1 · price: Each Series B1 and B2 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date. Read SEC document |
| May 28, 2019 Filed May 31, 2019 21:12 UTC | BICYCLE THERAPEUTICS PLC BCYC · Entity 5993 | ConversionOrdinary Shares | 1,081,823 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-033169 · a4.xml · nonDerivative · entry 1 Cambridge Innovation Capital (Jersey) Ltd · CIK 0001776911 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,081,823 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Series B1 and B2 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.